|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/19/22 Axim Biotechnologies, Inc. 8-K:1,7,9 9/15/22 13:374K Southridge Svcs Inc./FA |
Document/Exhibit Description Pages Size
1: 8-K Axim Biotechnologies, Inc. - Form 8-K SEC Filing HTML 22K
2: EX-10.1 September 15, 2022, License and Distribution HTML 106K
Agreement by and Between Axim Biotechnologies,
Inc. and Versea Ophthalmics, LLC
3: EX-99.1 Press Release HTML 16K
8: R1 Document and Entity Information HTML 42K
11: XML IDEA XML File -- Filing Summary XML 14K
9: XML XBRL Instance -- axim-20210915_htm XML 13K
10: EXCEL IDEA Workbook of Financial Reports XLSX 8K
4: EX-101.DEF XBRL Definitions -- axim-20210915_def XML 10K
5: EX-101.LAB XBRL Labels -- axim-20210915_lab XML 63K
6: EX-101.PRE XBRL Presentations -- axim-20210915_pre XML 43K
7: EX-101.SCH XBRL Schema -- axim-20210915 XSD 12K
12: JSON XBRL Instance as JSON Data -- MetaLinks 15± 24K
13: ZIP XBRL Zipped Folder -- 0001096906-22-002280-xbrl Zip 76K
| AXIM BIOTECHNOLOGIES, INC. - Form 8-K SEC filing |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________
FORM i 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): i September 15, 2022
i AXIM BIOTECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
i Nevada |
|
| i 27-4092986 | |
(State or other jurisdiction of incorporation)
|
| (Commission File Number) |
| (I.R.S. Employer Identification No.) |
i 6191 Cornerstone Court, i E., Suite 114 i San Diego, i California |
| i 92121 |
(Address of principal executive offices) |
| (Zip Code) |
i 858- i 923-4422
(Registrant’s telephone number, including area code)
(Former name if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
i ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 1.01 Entry into a Material Definitive Agreement.
On September 19, 2022, AXIM Biotechnologies, Inc. (“AXIM”) issued a press release which announced that AXIM had entered into a five (5) year License and Distribution Agreement (“Agreement”) with Verséa Ophthalmics, LLC (“Verséa”) for the global sale and distribution of its proprietary ocular diagnostic solutions.
The Agreement provides Verséa with the exclusive right to commercialize AXIM’s proprietary portfolio of point-of-care lab tests as well as its associated reader and includes three of AXIM’s key biomarker tests: the Ocular Immunoglobulin E (IgE) test, the Lactoferrin test, and the future MMP-9 test. Each test is designed for use at the point of care and is read by AXIM’s associated test reader system. Each test requires the collection of 0.5 microliters in tears and provides quantitative results in under 10 minutes, an industry-leading return time. Verséa plans to launch both the novel IgE and Lactoferrin tests at the 2022 American Academy of Ophthalmology and Optometry conferences. The MMP-9 test is anticipated to follow in the next 18-24 months. The to comply with the terms of the Agreement, Verséa must satisfy specified annual minimum sales commitments and product purchases.
Item 7.01 Regulation FD Disclosure
The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Item 9.01 - Financial Statements and Exhibits
(d) Exhibits
Exhibit # |
| Description |
|
|
|
10.1 |
| |
|
|
|
99.1 |
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AXIM BIOTECHNOLOGIES, INC. | |
|
|
|
Dated: September 19, 2022 | By: |
|
|
| Name: John Huemoeller, II |
|
| Chief Executive Officer |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 9/19/22 | None on these Dates | ||
| For Period end: | 9/15/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/02/23 Axim Biotechnologies, Inc. S-1 86:10M Southridge Svcs Inc./FA |